Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)
- 1 February 2009
- journal article
- clinical trial
- Published by Elsevier in European Journal of Radiology
- Vol. 69 (2) , 204-208
- https://doi.org/10.1016/j.ejrad.2008.10.009
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response CriteriaJournal of Clinical Oncology, 2007
- Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patientsEuropean Journal of Radiology, 2005
- Treatment of Gastrointestinal Stromal Tumors with Imatinib Mesylate:A Major Breakthrough in the Understanding of Tumor‐specific Molecular CharacteristicsWorld Journal of Surgery, 2005
- Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571World Journal of Gastroenterology, 2005
- CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A Quantitative Analysis Correlated with FDG PET FindingsAmerican Journal of Roentgenology, 2004
- The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- The RECIST criteria: implications for diagnostic radiologistsThe British Journal of Radiology, 2001
- STI571European Journal Of Cancer, 2001